albertsons diamond bar

Boosh Begins US Export With 16,000 Units

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is pleased to announce it has begun its US expansion with the first shipment of 16,000 units to its US distribution warehouse. The shipment includes an equal portion of our six frozen entrees; Shepard's Pie with Beyond Meat™, Rustic Pot Pie, Mexican Fiesta Bowl, Coconut Curry Cali, Mac & Cheeze & Peas and Veggie Bolognese with Beyond Meat™.

"As we have begun to send samples to our US food broker to distribute to key accounts in the US the feedback has been extremely positive. In fact, our first shipment to the US distribution center was anticipated to be 10,000 units, however, because of the high interest, we've increased it to 16,000 units," states founder and president Connie Marples.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7944/101127_bfac408fe451fbde_002.jpg

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7944/101127_bfac408fe451fbde_002full.jpg

After an extended search, Boosh is proud to announce the hiring of TJ Walsh as VP of Sales for North America. Boosh's recently formed sales department will be reporting to TJ, who will be responsible for all sales strategy, development, direction and budget. TJ will be developing on-site sales training and policy formulation, and will report directly to the president, Connie Marples, and CEO Jim Pakulis. He has extensive sales experience including, but not limited, to National Director of Sales for Silver Hills, a plant-based bakery and organic foods company. Prior to that he was Sales Manager for UNFI, North America's largest all natural and organic distributor. Previously he spent eight years with Bolthouse Farms eventually being promoted to Director of Field Sales. At Bolthouse Farms he was responsible for implementing a multi-million dollar sales budget, overseeing 30 sales representatives, developing strategic growth plans for selling all new product lines, and creating merchandising and sales strategies for Walmart, Kroger, Target, Safeway/Albertsons, HEB, Loblaws, Save On, Kroger's and Whole Foods.

"The timing of our first shipment to the US is aligning perfectly with the hiring of TJ. As we've grown the SKU count from 6 at the beginning of the year to 24 SKU's today, we'll be needing to expand our North American sales department, and we believe TJ is the perfect candidate for the undertaking. And the fact he grew up in the US and now resides in Vancouver is another major advantage for Boosh," states CEO Jim Pakulis.

"I have over fourteen years of either selling or overseeing sales teams in the natural food industry, both in the US and Canada. With my comprehensive knowledge and deep relationships with grocery store buyers, I believe I'll be a strong asset and will provide sales leadership as we continue to expand our retail footprint throughout North America," states TJ Walsh.

In other news, the Company retained the services of Globull Media LLC to provide investment relations services. The provider is charging the Company US fifty thousand dollars for one month of service.

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer
Telephone: (833) 882-6674
www.Booshfood.com

Investor Relations
Contact - Edge Communications Group
Email: invest@booshfood.com
Telephone: (236) 237-1315

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. We currently offer six frozen meals and three refrigerated meals which are sold throughout Canada. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101127

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the pricing of its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for gross proceeds of US$13.5 million before deducting the underwriting discounts and commissions and estimated expenses incurred in connection with the Offering.

The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

5 Top NASDAQ Biotech Stocks of 2024

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching a high of 4,954.813 on September 19.

While the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.5 percent from now to 2034, reaching a valuation of US$4.61 trillion.

Keep reading...Show less
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce the Company has filed a preliminary prospectus supplement (the "Supplement") to its short form base shelf prospectus dated July 12, 2024 (the "Base Prospectus") in connection with a proposed public offering (the "Offering") of Class A common shares (the "Common Shares"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the "SEC"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on July 16, 2024, in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Elixinol Wellness Limited

Strategic Acquisition and Capital Raising - Investor Presentation | 3 October 2024

Elixinol Wellness Ltd. (”EXL”) has entered into a binding agreement to acquire 100% of the business assets from the entities ("Acquisition") that together form The Healthy Chef business ("Healthy Chef").

Keep reading...Show less
Radiopharm Theranostics

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce regulatory and manufacturing progress for its B7-H3 targeting radio-antibody, BetaBart.

Keep reading...Show less
Hydralyte

Completion of Divesture of Non-US Assets

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte US” or “the Company”) refers to its announcement released pre-open on 2 October 2024 regarding entry into an Intellectual Property Sales Agreement (the ‘Agreement’) and related documents with Prestige Consumer Healthcare Inc. and associated subsidiaries.

Keep reading...Show less

Latest Press Releases

Related News

×